A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab in Adult Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice.
Sponsor: Eli Lilly and Company
Listed as NCT06864026, this PHASE4 trial focuses on Overweight or Obesity and Psoriatic Arthritis and remains actively recruiting participants. Sponsored by Eli Lilly and Company, it has been updated 10 times since 2025, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE4
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE4
-
Dec 2025 — Jan 2026 [monthly]
Recruiting PHASE4
-
Nov 2025 — Dec 2025 [monthly]
Recruiting PHASE4
-
Oct 2025 — Nov 2025 [monthly]
Recruiting PHASE4
▶ Show 5 earlier versions
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE4
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE4
-
Jul 2025 — Aug 2025 [monthly]
Recruiting PHASE4
-
May 2025 — Jul 2025 [monthly]
Recruiting PHASE4
-
Apr 2025 — May 2025 [monthly]
Recruiting PHASE4
First recorded
Mar 2025
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .